Article Per Year (5 Year)
p-Index From 2019 - 2024
0.778
P-Index
This Author published in this journals
All Journal Bioscientia Medicina : Journal of Biomedicine and Translational Research Bioscientia Medicina : Journal of Biomedicine and Translational Research
Drajad Priyono
Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Chronic Kidney Disease Related to Cognitive Disorders in the Elderly: A Narrative Literature Review Ajat Sudrajat; Drajad Priyono; Harnavi Harun; Roza Kurniati; Roza Mulyana
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 14 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i14.663

Abstract

Chronic kidney disease (CKD) is characterized by progressive and irreversible kidney damage, leading to the inability of the kidneys to perform their functions. Chronic kidney disease causes hypertension, anemia, vascular dysfunction, uremia, proteinuria, systemic inflammation, and oxidative stress associated with cognitive impairment. Age is a population group aged 60 years or more at risk of experiencing health problems and the consequences associated with CKD. One of the common comorbidities experienced by elderly patients with CKD is cognitive impairment. Current treatment options for CKD with cognitive impairment aimed at common risk factors, including angiotensin converting enzyme inhibitors (ACEI) and, angiotensin receptor blockers (ARBs), SGLT-2 inhibitors., GLP-1 RA, and DPP-4 inhibitors. Other interventions, such as erythropoietin (EPO) compensation and reduction of inflammation and oxidative stress, can help improve patients' clinical symptoms. This literature review aims to describe the relationship between chronic kidney disease and cognitive disorders that occur in the elderly.
Chronic Kidney Disease Related to Cognitive Disorders in the Elderly: A Narrative Literature Review Ajat Sudrajat; Drajad Priyono; Harnavi Harun; Roza Kurniati; Roza Mulyana
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 14 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i14.663

Abstract

Chronic kidney disease (CKD) is characterized by progressive and irreversible kidney damage, leading to the inability of the kidneys to perform their functions. Chronic kidney disease causes hypertension, anemia, vascular dysfunction, uremia, proteinuria, systemic inflammation, and oxidative stress associated with cognitive impairment. Age is a population group aged 60 years or more at risk of experiencing health problems and the consequences associated with CKD. One of the common comorbidities experienced by elderly patients with CKD is cognitive impairment. Current treatment options for CKD with cognitive impairment aimed at common risk factors, including angiotensin converting enzyme inhibitors (ACEI) and, angiotensin receptor blockers (ARBs), SGLT-2 inhibitors., GLP-1 RA, and DPP-4 inhibitors. Other interventions, such as erythropoietin (EPO) compensation and reduction of inflammation and oxidative stress, can help improve patients' clinical symptoms. This literature review aims to describe the relationship between chronic kidney disease and cognitive disorders that occur in the elderly.
The Effectiveness of Antiplatelet Therapy in COVID-19 Patients: A Narrative Literature Review Muhammad Ridhwan Fatharanifurqan; Rudy Afriant; Raveinal; Fauzar; Drajad Priyono
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 1 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i1.751

Abstract

Coagulopathy is a feature of severe COVID-19 disease and contributes to an increased risk of thromboembolic complications and death. This literature review aimed to describe the effectiveness of antiplatelet therapy in COVID-19 patients. There is an inverse relationship between the likelihood of COVID-19 infection, duration of illness and death, and use of antiplatelets for primary prevention. A study showed that COVID-19 patients who did not receive antiplatelet drugs had three times the risk of dying with antiplatelet drugs. This study shows the strong effect of antiplatelet drugs on reducing the mortality rate of COVID-19 patients. Another study showed that COVID-19 patients who received antiplatelet drugs had 1.18 times the risk of dying than those without antiplatelet drugs. This study shows that antiplatelet therapy does not affect the reduction in mortality in patients hospitalized with COVID-19. In conclusion, the effectiveness of antiplatelet administration in COVID-19 patients is still unclear, so further research is needed.
The Effectiveness of Antiplatelet Therapy in COVID-19 Patients: A Narrative Literature Review Muhammad Ridhwan Fatharanifurqan; Rudy Afriant; Raveinal; Fauzar; Drajad Priyono
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 1 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i1.751

Abstract

Coagulopathy is a feature of severe COVID-19 disease and contributes to an increased risk of thromboembolic complications and death. This literature review aimed to describe the effectiveness of antiplatelet therapy in COVID-19 patients. There is an inverse relationship between the likelihood of COVID-19 infection, duration of illness and death, and use of antiplatelets for primary prevention. A study showed that COVID-19 patients who did not receive antiplatelet drugs had three times the risk of dying with antiplatelet drugs. This study shows the strong effect of antiplatelet drugs on reducing the mortality rate of COVID-19 patients. Another study showed that COVID-19 patients who received antiplatelet drugs had 1.18 times the risk of dying than those without antiplatelet drugs. This study shows that antiplatelet therapy does not affect the reduction in mortality in patients hospitalized with COVID-19. In conclusion, the effectiveness of antiplatelet administration in COVID-19 patients is still unclear, so further research is needed.
Co-Authors Ajat Sudrajat Fauzar Harun Harnavi Muhammad Ridhwan Fatharanifurqan Raveinal Roza Kurniati Roza Mulyana Rudy Afriant